Key Highlights

  • On November 18, Elevance Health (NYSE:ELV) lost 7.63%, Centene fell 7.03% and CVS Health slid 5.20%.
  • Molina Healthcare was about 4.97% lower in the afternoon as the selling spread across managed care.
  • The proposal, dubbed the CRUSH rule, would project Medicare Advantage audit errors onto entire contracts reaching back to 2018.
  • CMS projects roughly USD 90.2 billion in recoveries over 2027 through 2036, with comments due January 19, 2027.

Selling Reaches Beyond the Industry Leaders

Humana and UnitedHealth posted the steepest falls on Wednesday, yet the proposal also hit the wider managed care group hard. Elevance lost 7.63%, Centene 7.03%, and CVS Health, parent of Aetna, 5.20%. Molina was 4.97% lower early in the afternoon. Health care shed 2.20%, the second-weakest sector in the S&P 500 after energy. Each decline broadly tracked how much a company relies on Medicare Advantage. Elevance's large commercial and Medicaid operations give it ballast, although its Medicare Advantage membership has grown in recent years. Centene's Medicare plans are smaller than its Medicaid and marketplace businesses. CVS Health was partly cushioned by its pharmacy and benefit management arms. The breadth of the decline suggests investors see a sector-wide problem rather than one confined to a couple of names, and they are treating the whole group as exposed until each company explains its position.

The Mechanics Behind the CRUSH Proposal

Auditors check whether the diagnoses are backed by records. The Centers for Medicare and Medicaid Services unveiled the proposal on November 16 to target improper payments in Medicare Advantage, where plans collect more for members whose documented conditions are more complex. Under the plan, an error rate found in a sample would be extended across the whole contract, so a modest finding could become a sizeable repayment reaching back to payments made from 2018. CMS noted that a federal court in Texas set aside comparable provisions of a 2023 rule on procedural grounds and that the agency is reissuing them. It estimates the rule would recover roughly USD 90.2 billion between 2027 and 2036. Publication in the Federal Register is set for November 19, with comments due by January 19, 2027, so a final rule or revision is unlikely before early next year at the earliest.

How Shareholders Could React

Near term, the shares will probably trade on estimates of each insurer's exposure. No company has yet quantified how much of the USD 90.2 billion it might owe, and those figures will shape valuations. Some investors had already trimmed managed care holdings this year over rising medical costs, so part of the risk may have been priced in earlier this week. Even so, a two-day drop of this size suggests the market was not fully prepared. Rates matter too. With the 10-year Treasury Yield near 5.07% and Fed minutes signalling more hikes, defensive names such as health insurers compete with higher bond yields. Legal challenges are also possible, given the earlier court ruling. In the coming weeks, attention will turn to company statements, industry commentary and any sign from Washington that the proposal may be softened before it is final. Until then the group is likely to stay among the most volatile parts of health care.

Where Things Stand

Elevance, Centene, CVS Health and Molina slid as the CRUSH proposal raised the prospect of large Medicare Advantage repayments. Company company estimates of exposure and the comment cutoff on January 19, 2027 are the signals to watch next.